Deakin University
Browse

File(s) under permanent embargo

Biomarkers for Deep Brain Stimulation in Animal Models of Depression

journal contribution
posted on 2021-01-01, 00:00 authored by Jason Yuen, Aaron E Rusheen, Joshua Blair Price, Abhijeet S Barath, Hojin Shin, Abbas KouzaniAbbas Kouzani, Michael BerkMichael Berk, Charles D Blaha, Kendall H Lee, Yoonbae Oh
Objectives

Despite recent advances in depression treatment, many patients still do not respond to serial conventional therapies and are considered “treatment resistant.” Deep brain stimulation (DBS) has therapeutic potential in this context. This comprehensive review of recent studies of DBS for depression in animal models identifies potential biomarkers for improving therapeutic efficacy and predictability of conventional DBS to aid future development of closed-loop control of DBS system.
Materials and Methods

A systematic search was performed in Pubmed, EMBASE, and Cochrane Review using relevant keywords. In overall, 56 animal studies satisfied the inclusion criteria.
Results

Outcomes were divided into biochemical/physiological, electrophysiological, and behavioral categories. Promising biomarkers include biochemical assays (in particular, microdialysis and electrochemical measurements), which provide real-time results in awake animals. Electrophysiological tests, showing changes at both the target site and downstream structures also revealed characteristic changes at several anatomic targets (such as the medial prefrontal cortex and locus coeruleus). However, the substantial range of models and DBS targets limits the ability to draw generalizable conclusions in animal behavioral models.
Conclusions

Overall, DBS is a promising therapeutic modality for treatment-resistant depression. Different outcomes have been used to assess its efficacy in animal studies. From the review, electrophysiological and biochemical markers appear to offer the greatest potential as biomarkers for depression. However, to develop closed-loop DBS for depression, additional preclinical and clinical studies with a focus on identifying reliable, safe, and effective biomarkers are warranted.

History

Journal

Neuromodulation: Technology at the Neural Interface

Article number

ner.13483

Pagination

1 - 10

Publisher

Wiley

Location

London, Eng.

ISSN

1094-7159

eISSN

1525-1403

Language

eng

Publication classification

C1 Refereed article in a scholarly journal